Affymetrix Inc. (Nasdaq: AFFX) announced that its technology powers the Ipsogen MapQuant Dx” Genomic Grade, the first genomic test designed to provide a more precise measurement of tumor grade than previous techniques. Ipsogen, a leading French molecular diagnostic company, launched the test, which resulted from the Powered by Affymetrix” agreement signed in August 2007.